Table 3. Dose levels, number of cycles administered and dose-limiting toxicities.
|
Dose (mg m−2) |
|||||
|---|---|---|---|---|---|
| Dose level | Ispinesib | Docetaxel | n | No. of cycles | DLT |
| 0 | 8 | 60 | 6 | 20 | 1 – prolonged grade 4 neutropaenia |
| +1 | 8 | 75 | 6 | 26 | 2 – prolonged grade 4 neutropaenia and febrile neutropaenia |
| A | 10 | 60 | 3 | 12 | 0 |
| A1 | 12 | 60 | 6 | 25 | 3a – prolonged grade 4 neutropaenia |
| Ae | 10 | 60 | 3 | 16 | 0 |
A=alternative dose level; Ae=expansion of cohort A at MTD; n=number of patients; No.=number.
a
⩾2 DLTs in cohort due to simultaneous enrolment of patients.